Simplex Trading
CCCC icon

Simplex Trading’s C4 Therapeutics CCCC Stock Holding History

Simplex Trading’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,658
Closed -$72.2K – 9131
2025
Q4 		$58.6K Buy
30,658
+22,822
+291% +$54.1K ﹤0.01% 5519
2025
Q3 		$17K Buy
+7,836
New +$18.8K ﹤0.01% 7444
2025
Q1 		– Sell
-6,871
Closed -$20.5K – 8603
2024
Q4 		$24K Sell
6,871
-73,628
-91% -$366K ﹤0.01% 6522
2024
Q3 		$458K Buy
80,499
+38,398
+91% +$231K ﹤0.01% 3682
2024
Q2 		$194K Sell
42,101
-7,168
-15% -$42.8K ﹤0.01% 4675
2024
Q1 		$402K Sell
49,269
-45,751
-48% -$355K ﹤0.01% 4070
2023
Q4 		$536K Buy
+95,020
New +$217K ﹤0.01% 3621
2023
Q1 		– Sell
-44
Closed -$259 – 9092
2022
Q4 		$0 Sell
44
-2,145
-98% -$17.8K ﹤0.01% 9276
2022
Q3 		$19K Sell
2,189
-172
-7% -$1.79K ﹤0.01% 7564
2022
Q2 		$17K Sell
2,361
-34,885
-94% -$307K ﹤0.01% 7757
2022
Q1 		$903K Buy
+37,246
New +$904K ﹤0.01% 3038

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Simplex Trading's CCCC Position: Q1 2026 in Review

Simplex Trading sold out of C4 Therapeutics (CCCC) in Q1 2026, closing a stake of 30,658 shares — an estimated $72.2K sold.

Simplex Trading first reported a position in CCCC in Q1 2022 and held it in 11 quarters. The position peaked at $903K in Q1 2022. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Simplex Trading reported no remaining C4 Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Simplex Trading sold 30,658 C4 Therapeutics shares in Q1 2026, an estimated $72.2K.
  • Simplex Trading first reported a position in C4 Therapeutics in Q1 2022 and held it in 11 quarters.
  • Simplex Trading's C4 Therapeutics position peaked at $903K in Q1 2022.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.